title: Endocrine and clinical effects of leuprolide in prostatic cancer.
abstract: Twenty-nine subjects with metastatic carcinoma of the prostate received daily subcutaneous injections of leuprolide, a luteinizing hormone-releasing hormone analog. After transient gonadotropin and androgen stimulation, leuprolide induced long-term suppression of serum testosterone and gonadotropins production. In 25 subjects there was objective disease stabilization or tumor regression. Eleven subjects subsequently relapsed (median = 10 mo) after initiation of treatment. Except for vasomotor hot flashes, leuprolide appears to be well tolerated by patients with advanced prostatic cancer.
mesh_terms: D000368:Aged; D004341:Drug Evaluation; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D016729:Leuprolide; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
chemical_list: D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D016729:Leuprolide